Basic Organization Information
The Leukemia & Lymphoma Society, Inc.
- Also Known As:
- Physical Address:
White Plains, NY
- Web URL:
- Blog URL:
- NTEE Category:
G Disease, Disorders, Medical Disciplines
H Medical Research
H30 Cancer Research
- Ruling Year:
The Leukemia & Lymphoma Society: We have one goal: A world without blood cancers
The Leukemia & Lymphoma Society (LLS) exists to find cures and ensure access to treatments for blood cancer patients. Today, LLS is the world’s largest voluntary health agency dedicated to finding cures for leukemia, lymphoma, myeloma and other blood cancers. LLS impacts patients and their families through their 61 chapters across the United States and Canada.
Mr. Louis J. DeGennaro, Ph.D.
Louis J. DeGennaro, Ph.D., was named interim president and CEO of The Leukemia & Lymphoma Society (LLS) in February 2014. DeGennaro has been a critical member of the LLS executive leadership team since he joined LLS in 2005.
As a member of the leadership team, DeGennaro helped steward LLS operations. He was named LLS chief mission officer in 2009, with responsibility for leadership of LLS's mission functions of research, patient access, education, public policy and advocacy. He continues to serve as chief mission officer with his role as interim president and CEO.
DeGennaro is recognized as a key architect of LLS's cures and access agenda to help save lives of blood cancer patients and the LLS Therapy Acceleration Program® - a venture philanthropy endeavor that demonstrates the role of nonprofit organizations in supporting drug discovery and development with the biotechnology industry.
DeGennaro received his Ph.D. in biochemistry from the University of California at San Francisco and did his postdoctoral research at Yale University School of Medicine. His previous academic appointments include research group leader at Max Planck Institute in Munich, Germany, and associate professor of neurology and cell biology at the University of Massachusetts Medical School.
DeGennaro has more than 25 years of research and executive management experience. His private-sector positions include senior director of molecular genetics at Wyeth Pharmaceuticals, Princeton, NJ, and executive vice president for research and development, SynX Pharma, Inc., Toronto, Canada.
Officers for Fiscal Year (IRS Form 990)
Highest Paid Employees & Their Compensation (IRS Form 990)
Patient Services and Blood Cancer Research/Advocacy
Diseases, Disorders & Medical Disciplines
- Population Served:
hands to help patients cope: improving the
quality of life of patients and their families. The Leukemia & Lymphoma
Society offers the most comprehensive array of services to patients and
families touched by blood cancers.
A diagnosis of leukemia, lymphoma or myeloma brings many daily challenges.
The Society is committed to providing support and guidance to patients and the
health professionals who care for them.
- The Information Resource Center (IRC) provides the public, families, health
professionals and people living with blood-related cancer accurate, up-to-date,
disease-related information and referral services
Investing in blood cancer research:
LLS has invested more than $680 million in research, approximately $69 million
in fiscal year 2009 alone. Programs like the Specialized Center of
Research (SCOR), which brings together teams of scientists from different
disciplines and our Translational Research Program, which funds research with a
high probability of producing innovative patient treatments in an accelerated
time frame, have directly contributed to many breakthrough cancer
Research funded by LLS has led or contributed to advances such as
chemotherapy, bone marrow and stem cell transplantation and new, targeted oral
therapies such as Gleevec®.
Providing critical information and support for patients and their
We made 4.9 million contacts with patients, caregivers and healthcare
professionals in fiscal year 2009, through our Information Resource Center
(IRC), our award winning Web site and community-based patient service
programs. We put people together with experts through Web-casts and
teleconferences, and provided professional education through seminars, to
extend the latest findings to a broader professional audience.
for issues impacting blood cancer patients:
With more than 20,000 advocacy volunteers throughout the country, our voice is
being heard by those responsible for legislation to fund blood cancer research
and educational programs.
Program Long-Term Success:
Program Short-Term Success:
Program Success Monitored by:
Program Success Examples:
Contractor data is available for this organization!
Independent Contractor information for 2012, 2011, 2010, 2009, 2008 is available for this organization with a subscription to GuideStar Premium Pro.
GuideStar Premium Pro also includes:
- Comprehensive financial data, including functional expense detail, for every digitized fiscal year in GuideStar's database
- Ability to download up to 55 fields of data for up to 1,000 organizations at a time and up to five years worth of Income Statement
and Balance Sheet data for individual organizations
- Comprehensive advanced search capabilities, including criteria for functional expenses, investible assets, investment income
and audit & 990T filing requirements
- Ability to save organizations and searches for quick reference
- People search with salary range data
- Access to all available Forms 990
Impact Summary from the Nonprofit
As of 2014, LLS has invested nearly $1 billion in research to advance therapies and save lives. From 2000 through 2013, almost 40 percent (31 of 81) of new anti-cancer drugs were FDA-approved for blood cancer patients, more first-ever approvals than for any other group of cancers, and many of these were advanced with funding from LLS. Many of these therapies are also helping patients with other cancers and other serious diseases.
LLS is the leading source of free blood cancer information, education and support for patients, survivors, families and healthcare professionals. In North America, LLS’s co-pay assistance program has raised more than $200 million to date to help eligible blood cancer patients afford health-insurance premiums and prescription drug co-pays, assisting more than 36,000 patients since its inception in 2007.
LLS also advocates for policies at the federal and state levels to accelerate the approval of new treatments and ensure access to quality, affordable and coordinated care.
For more in-depth information about this organization's impact, view their latest annual report http://www.lls.org/aboutlls/financialinformation/annualreports/
Expert Reviews and Comments
Evidence of Impact
The Leukemia & Lymphoma Society has improved the state of various blood cancers by increasing funds to conduct research and by providing education and financial services to patients.
This organization's leadership team, its way of dealing with and recruiting volunteers, and its effective marketing strategies are reasons why the group has been so effective, according to experts.
Areas for Improvement
Experts have noted that the Leukemia & Lymphoma Society could improve by engaging in more collaborations, expanding more into the realm of policy, and hiring more staff.